Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ATP-sensitive potassium (KATP) channel in pancreatic beta cells is an octameric protein complex consisting of four Kir6.2 and four SUR1 subunits. It couples the cell’s metabolic state to its electrical activity, regulating insulin secretion. High intracellular ATP levels cause channel closure, leading to depolarization and insulin release, while low ATP levels open the channel, hyperpolarizing the membrane and inhibiting insulin release. It is the target of sulfonylurea drugs and mutations in its genes (*KCNJ11* and *ABCC8*) are associated with congenital hyperinsulinism and neonatal diabetes mellitus.
Sulfonylureas bind to SUR1 subunit causing closure of the channel, leading to cell depolarization and insulin release. Channel openers activate/open the channel via interaction with SURs.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP-Sensitive Potassium Channel (Pancreatic Beta Cell) (KATP channel).